Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3026 Target Snapshot

Gamma-aminobutyric acid receptor subunit alpha-3 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
133Compounds
23Assays
4Approved Drugs
85.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Gamma-aminobutyric acid receptor subunit alpha-3 shows clinical signal disease relevance led by anxiety. 2 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P34903. Start with anxiety, then reuse UniProt P34903 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with anxiety, then reuse UniProt P34903 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
anxiety

Gamma-aminobutyric acid receptor subunit alpha-3 shows clinical signal disease relevance led by anxiety. 2 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with anxiety because it currently carries clinical signal support. Linked drugs include AZD6280, AZD7325. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Gamma-aminobutyric acid receptor subunit alpha-3 as ChEMBL target CHEMBL3026, mapped to UniProt P34903. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Gamma-aminobutyric acid receptor subunit alpha-3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3026
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P34903
Gamma-aminobutyric acid receptor subunit alpha-3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Gamma-aminobutyric acid receptor subunit alpha-3 is the right protein anchor across sources, using UniProt P34903 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why anxiety is currently framed as clinical signal support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameGamma-aminobutyric acid receptor subunit alpha-3
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP34903
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelGamma-aminobutyric acid receptor subunit alpha-3
UniProt AccessionP34903
Component TypeProtein
Sequence Length492 aa

Gamma-aminobutyric acid receptor subunit alpha-3

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Gamma-aminobutyric acid receptor subunit alpha-3, mapped to UniProt P34903. Sequence length is 492 aa.

Mapped IDP34903
Review nameGamma-aminobutyric acid receptor subunit alpha-3
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Gamma-aminobutyric acid receptor subunit alpha-3 shows clinical signal disease relevance led by anxiety. 2 more disease programs remain visible in the same review block.

Clinical signal Phase II
anxiety
2 linked drugs · 2 direct · 2 efficacy
Linked drugAZD6280
Linked drugAZD7325
Clinical signal Phase II
autism spectrum disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugAZD7325
Clinical signal Phase I
fragile X syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugAZD7325
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with anxiety because it currently carries clinical signal support. Linked drugs include AZD6280, AZD7325. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseanxiety
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Approved
3
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC503.0
KI59.0
EC5023.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL45198 9.3 Ki 0.5 Preclinical
CHEMBL306422 9.21 Ki 0.61 Preclinical
CHEMBL373250 9.15 Ki 0.7 Preclinical
CHEMBL363211 9.11 Ki 0.77 Preclinical
CHEMBL301605 9.0 Ki 1.0 Preclinical
CHEMBL407 9.0 Ki 1.0 Approved
CHEMBL1783282 8.89 Ki 1.3 Clinical
CHEMBL204696 8.74 Ki 1.8 Preclinical
CHEMBL5280240 8.7 Ki 2.0 Preclinical
CHEMBL49141 8.7 Ki 2.0 Preclinical
Distribution

pChEMBL Value Distribution

2
5.0
2
5.5
16
6.0
11
6.5
10
7.0
19
7.5
7
8.0
5
8.5
7
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

ZOLPIDEM
CHEMBL911
Approved 1992
Properties Compare Identifier
FLUMAZENIL
CHEMBL407
Approved 1991
Properties Compare Identifier
ALPRAZOLAM
CHEMBL661
Approved 1981
Properties Compare Identifier
DIAZEPAM
CHEMBL12
Approved 1963
Properties Compare Identifier
Assay Landscape

Assay Landscape

23
Total Assays
76
Tested Compounds
2
Assay Types
Binding — 21 assays, 76 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 17 69 7.4
cell-based format 4 7 6.2
ADME — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine